KEY DETAILS
A new phase 4 trial will test semaglutide alongside coaching for 880 people with obesity awaiting kidney transplants, starting January 2027.
The FDA warned Cheap Medicine Shop for selling unapproved semaglutide, since unlicensed sellers risk counterfeit or contaminated drugs.
Online Generic Medicine faced an FDA shutdown for selling unapproved semaglutide under a fake brand, flagged as unsafe and uncontrolled.
A phase 3 study found the oral GLP-1 pill safiglipron works as well as dapagliflozin for type 2 diabetes when metformin alone isn't enough.
This week brought a mix of encouraging research and necessary warnings for anyone following GLP-1 drugs. A new oral option showed it can hold its own against an established diabetes medication, while federal regulators moved again against sellers peddling unapproved versions of semaglutide. Together, these updates point to the same lesson: real progress on GLP-1 treatments is happening through legitimate trials and approved channels, not through unregulated online sellers. That distinction matters if you're considering any GLP-1 medication for yourself or a family member.
Patients with obesity who are waiting for a kidney transplant often face an added hurdle: many transplant programs set weight-related criteria before they will proceed. The upcoming phase 4 trial will examine whether semaglutide, combined with virtual coaching, can help patients meet those criteria and move forward with transplantation. Enrollment of 880 participants is set to begin in January 2027, which means results will not be available for some time. For patients and families currently facing transplant waitlists, this trial signals that researchers are looking specifically at how GLP-1 drugs might support this group, though no conclusions can be drawn until the study is complete.
The FDA's warning letter to Cheap Medicine Shop addresses a problem that has become familiar: online sellers offering semaglutide without the approvals that ensure a drug's safety and quality. Unlike pharmacies that operate within FDA oversight, these unlicensed sellers aren't required to prove their products contain the correct ingredients in the correct amounts. That gap creates real risk, since buyers have no way to confirm whether what they receive is counterfeit or contaminated. Anyone considering a GLP-1 medication should treat the source of that medication as seriously as the decision to take it at all.
A second case this same week involved Online Generic Medicine, which the FDA shut down for selling unapproved semaglutide under a fabricated brand name. Using a fake brand can make a product look legitimate to someone searching for a known medication, which is part of why the agency flagged it as both unsafe and uncontrolled. The timing of this action, alongside the Cheap Medicine Shop warning, suggests the FDA is actively tracking multiple sellers rather than responding to a single isolated case. Patients who have purchased semaglutide online, particularly from unfamiliar brands, may want to check whether that seller has appeared in an FDA warning before continuing to use the product.
The phase 3 trial results for safiglipron offer a different kind of update, focused on expanding treatment options rather than policing bad actors. In this study, the oral pill performed as well as dapagliflozin, an established type 2 diabetes drug, for patients whose blood sugar wasn't adequately controlled by metformin alone. Because safiglipron is taken as a pill rather than injected, a result like this could matter for patients who prefer or need an oral option. The study was randomized, double-blind, and compared directly against an active treatment rather than a placebo, which strengthens confidence in the comparison.
If you're exploring GLP-1 treatment, the clearest takeaway from this week is to rely on two things: your prescribing physician and FDA-approved sources for the medication itself. Research into new formulations and new patient groups continues to move forward through proper trials, and that progress is worth watching. But none of it changes the risk posed by unlicensed online sellers, who remain a separate and ongoing problem. Staying informed about both tracks, the legitimate research and the regulatory warnings, will serve you better than following either one alone.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.